PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.06), $0.30 worse than the analyst estimate of ($0.76). Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE